Dr. Ignacio Melero, co-director of the Immunology and Immunotherapy Program of the Cima University of Navarra, integrated in the Cancer Center Clínica Universidad de Navarra, has received the XX award of research Burdinola. The award distinguishes the work of Dr. Melero in the field of biomedical research , especially in cancer immunotherapy.

The submission of the XX award of research Burdinola, held at Cima University of Navarra, was chaired by the Vice President of research and Sustainability of the University of Navarra, Paloma Grau, accompanied by José Andrés Gómez Cantero, director general of Cima, Joseba Campos, director general of Clínica Universidad de Navarra and Mikel Martínez, director general of Burdinola S.Coop, who made submission of diploma and the economic endowment of 15,000 €.

Dr. Jesús San Miguel, consultant senior of the Clínica Universidad de Navarra and former director of Translational Medicine of the Cima, presented the award winner as "one of the pioneers in the research of cancer immunotherapy, with an eye always on the patient".

attendance The event was attended by Ana Burusco, general director of Universities of the Government of Navarra and Joseba Pineda, president of the Burdinola Awards and Dean of the School Medicine and Nursing UPV- EHU, who read the certificate of the jury.

Pioneer in immunotherapy

Dr. Melero leads since 1998 a team multidisciplinary from Cima University of Navarra working on immunotherapy with cell therapy techniques, gene therapy and monoclonal antibodies at the Cancer Center Clínica Universidad Navarra. He has recently been appointed Full Professor (Kidani Chair of Oncology) at the University of Oxford. He combines his activity at the University of Navarra with research in OXCIO, the Oxford Center of Immuno-oncology, a nascent center dependent on the Departments of Medicine and Oncology of the English university.

Throughout his career he has been researcher principal in more than 44 immunotherapy clinical trials. His work has mainly focused on translational research in cancer immunotherapy. His most notable contributions focus on immunotherapy strategies based on the 4-1BB (CD137) receptor and his pioneering work on liver cancer immunotherapy that has transformed medical internship .

award from research Burdinola

Burdinola is a Biscayan cooperative specialized in the planning and integration of laboratories present in many countries around the world.

Since 1993 submission a award to the research to recognize, value and stimulate the work of the academic community, as part of its commitment to promote science in Spain.